| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d2536d25c606cf230e24d4f94045e92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eabbfd26d0cea1347c3425952c64e858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c16f02d8702c5ededf995b2e24204d47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ea47a4d0d0067db3ec642e553905144
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_153ae69eed34c3caf715379b30dd185f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d40960190e37af1e3390c21a67554f98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49e9b44fcf9f24b56804190c76985a9d |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M1-36 |
| filingDate |
2004-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2006-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_170c56149263397194a08dd5749be140
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32aa0aa065db0fe053f2a4f1c7da51f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ea62f6ea909f11d7adee41a72a2c850
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75647f722b5205f7e72878a7b8e49b88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f14cc73932cbacccb76d646887da425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f77d685eea14bb3ff1414dfecc8b1c96 |
| publicationDate |
2006-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2280452-C2 |
| titleOfInvention |
Method for treating hodgkin lymphoma cases |
| abstract |
FIELD: medicine. n SUBSTANCE: method involves taking 400 ml of patient blood before beginning treatment. Plasma is separated. 15 ml of auto plasma is taken and incubated with 9x10 6 MU of recombinant interferon α2b for 1 h at t 37°C and endolymphatically introduced to the patient at the first treatment day. The rest of the autoplasma is divided into two equal portions and saved in refrigerator. Next day, one autoplasma portion is taken and incubated with chemopreparations for 30 min at t 37°C in standard doses. Doxorubicin, Bleomycin, Vinbastin, Dacarbason are intravenously introduced as drop infusion. Said procedure of intravenous infusions of chemopreparations incubated with autoplasma is repeated at the ninth treatment day. 40 mg of prednisolone per day is introduced from the first to the tenth day. The treatment course is repeated when needed. n EFFECT: enhanced effectiveness of treatment. n 1 tbl |
| priorityDate |
2004-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |